NASDAQ:SGEN Seagen - SGEN Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Seagen Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $140.67 +0.98 (+0.70%) (As of 01/27/2023 12:00 AM ET) Add Compare Share Share Today's Range$138.82▼$141.0250-Day Range$117.37▼$140.6752-Week Range$105.43▼$183.00Volume869,706 shsAverage Volume876,566 shsMarket Capitalization$26.12 billionP/E RatioN/ADividend YieldN/APrice Target$161.21 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Seagen MarketRank™ ForecastAnalyst RatingModerate Buy2.75 Rating ScoreUpside/Downside14.6% Upside$161.21 Price TargetShort InterestHealthy1.62% of Shares Sold ShortDividend StrengthN/ASustainability-1.96Upright™ Environmental ScoreNews Sentiment0.01Based on 13 Articles This WeekInsider TradingSelling Shares$7.28 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($3.54) to ($2.30) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.44 out of 5 starsMedical Sector195th out of 1,055 stocksBiological Products, Except Diagnostic Industry36th out of 170 stocks 3.4 Analyst's Opinion Consensus RatingSeagen has received a consensus rating of Buy. The company's average rating score is 2.75, and is based on 12 buy ratings, 4 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $161.21, Seagen has a forecasted upside of 14.6% from its current price of $140.67.Amount of Analyst CoverageSeagen has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 3.0 Short Interest Percentage of Shares Shorted1.62% of the outstanding shares of Seagen have been sold short.Short Interest Ratio / Days to CoverSeagen has a short interest ratio ("days to cover") of 3.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Seagen has recently increased by 15.38%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldSeagen does not currently pay a dividend.Dividend GrowthSeagen does not have a long track record of dividend growth. Previous Next 3.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreSeagen has received a 45.57% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Brentuximab vedotin", "Tucatinib", and "Enfortumab vedotin" products. See details.Environmental SustainabilityThe Environmental Impact score for Seagen is -1.96. Previous Next 2.2 News and Social Media Coverage News SentimentSeagen has a news sentiment score of 0.01. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.70 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 13 news articles for Seagen this week, compared to 7 articles on an average week.Search Interest6 people have searched for SGEN on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.MarketBeat FollowsOnly 4 people have added Seagen to their MarketBeat watchlist in the last 30 days. This is a decrease of -43% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Seagen insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $7,278,459.00 in company stock.Percentage Held by Insiders27.30% of the stock of Seagen is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions86.25% of the stock of Seagen is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Seagen are expected to grow in the coming year, from ($3.54) to ($2.30) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Seagen is -40.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Seagen is -40.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSeagen has a P/B Ratio of 8.39. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Seagen (NASDAQ:SGEN) StockSeagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of advanced or metastatic urothelial cancer; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. It also develops TIVDAK for metastatic cervical cancer and other solid tumors; Ladiratuzumab Vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; Disitamab Vedotin, a novel HER2-targeted ADC; and SEA-CD40, SEA-TGT, SEA-BCMA, and SEA-CD70 for various cancer diseases. Seagen Inc. has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; Merck; and RemeGen, Co. Ltd. The company was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020. Seagen Inc. was incorporated in 1997 and is headquartered in Bothell, Washington.Read More Receive SGEN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Seagen and its competitors with MarketBeat's FREE daily newsletter. Email Address SGEN Stock News HeadlinesJanuary 27, 2023 | americanbankingnews.comSeagen Inc. (NASDAQ:SGEN) CMO Roger D. Dansey Sells 10,000 SharesJanuary 27, 2023 | americanbankingnews.comSeagen Inc. (NASDAQ:SGEN) Insider Jean I. Liu Sells 5,000 SharesJanuary 28, 2023 | Porter & Company (Ad)The Next Big Crisis Is HereYou just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.January 27, 2023 | americanbankingnews.comMorgan Stanley Cuts Seagen (NASDAQ:SGEN) Price Target to $170.00January 26, 2023 | americanbankingnews.comSeagen (NASDAQ:SGEN) PT Lowered to $170.00 at Berenberg BankJanuary 23, 2023 | americanbankingnews.comSVB Leerink Boosts Seagen (NASDAQ:SGEN) Price Target to $162.00January 20, 2023 | americanbankingnews.comSeagen Inc. (NASDAQ:SGEN) Insider Jean I. Liu Sells 578 SharesJanuary 19, 2023 | finance.yahoo.comSeagen Announces FDA Accelerated Approval of TUKYSA® (tucatinib) in Combination with Trastuzumab for People with Previously Treated RAS Wild-Type, HER2-Positive Metastatic Colorectal CancerJanuary 28, 2023 | Porter & Company (Ad)Is This The End of Capitalism?EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…January 19, 2023 | finance.yahoo.comSeagen to Host Conference Call and Webcast Discussion of Fourth Quarter and Full Year 2022 Financial Results on February 15, 2023December 20, 2022 | finance.yahoo.comSeagen, Astellas and Merck Announce FDA Acceptance of sBLAs for PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) for the First-Line Treatment of Certain Patients With Locally Advanced or Metastatic Urothelial CancerDecember 20, 2022 | finance.yahoo.comAstellas, Seagen and Merck Announce FDA Acceptance of Supplemental Biologics License Applications for PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) for the First-Line Treatment of Certain Patients With Locally Advanced or Metastatic Urothelial CancerDecember 12, 2022 | finance.yahoo.comSeagen Announces Results from Phase 2 Clinical Trial of ADCETRIS® (brentuximab vedotin) with Novel Immunotherapy Combination in Patients with Advanced- and Early-Stage Classical Hodgkin LymphomaDecember 7, 2022 | finance.yahoo.comSeagen Inc.'s (NASDAQ:SGEN) Intrinsic Value Is Potentially 98% Above Its Share PriceDecember 1, 2022 | finance.yahoo.comSeagen to Highlight ADCETRIS® (brentuximab vedotin) Clinical Progress at the 2022 American Society of Hematology (ASH) Annual MeetingNovember 17, 2022 | finance.yahoo.comInstitutional owners may consider drastic measures as Seagen Inc.'s (NASDAQ:SGEN) recent US$1.2b drop adds to long-term lossesNovember 10, 2022 | finance.yahoo.comSeagen Names David R. Epstein as Chief Executive Officer and DirectorNovember 10, 2022 | finance.yahoo.comSeagen Appoints Sandra M. Swain, M.D., to Board of DirectorsNovember 10, 2022 | finance.yahoo.comSeagen to Highlight New Research from its Diverse Pipeline of Targeted Cancer Therapy Candidates at the Society for Immunotherapy of Cancer’s (SITC) Annual MeetingNovember 10, 2022 | finance.yahoo.comSeagen Announces U.S. FDA Approval of New Indication for ADCETRIS® (brentuximab vedotin) for Children with Previously Untreated High Risk Hodgkin LymphomaOctober 31, 2022 | markets.businessinsider.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Seagen (SGEN), Alnylam Pharma (ALNY) and BioMarin Pharmaceutical (BMRN)October 27, 2022 | nasdaq.comSeagen Inc Q3 Loss decreases, but misses estimatesOctober 27, 2022 | seekingalpha.comSeagen Inc. (SGEN) Q3 2022 Earnings Call TranscriptOctober 27, 2022 | finance.yahoo.comSeagen Reports Third Quarter 2022 Financial ResultsOctober 25, 2022 | msn.comA Bearish Sign Appears On Seagen's ChartOctober 25, 2022 | msn.comWhat 9 Analyst Ratings Have To Say About SeagenOctober 19, 2022 | finance.yahoo.comInvesting in Seagen (NASDAQ:SGEN) five years ago would have delivered you a 116% gainSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive SGEN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Seagen and its competitors with MarketBeat's FREE daily newsletter. Email Address SGEN Company Calendar Last Earnings10/28/2021Today1/28/2023Next Earnings (Confirmed)2/15/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:SGEN CUSIP81257810 CIK1060736 Webwww.seattlegenetics.com Phone(425) 527-4000Fax425-527-4001Employees2,675Year Founded1998Price Target and Rating Average Stock Price Forecast$161.21 High Stock Price Forecast$188.00 Low Stock Price Forecast$135.00 Forecasted Upside/Downside+14.6%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage16 Analysts Profitability EPS (Most Recent Fiscal Year)($3.45) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-674,470,000.00 Net Margins-34.16% Pretax Margin-34.09% Return on Equity-21.56% Return on Assets-17.46% Debt Debt-to-Equity RatioN/A Current Ratio3.80 Quick Ratio3.30 Sales & Book Value Annual Sales$1.57 billion Price / Sales16.59 Cash FlowN/A Price / Cash FlowN/A Book Value$16.76 per share Price / Book8.39Miscellaneous Outstanding Shares185,660,000Free Float134,978,000Market Cap$26.12 billion OptionableOptionable Beta0.55 Social Links Key ExecutivesMr. Todd E. Simpson (Age 62)Chief Financial Officer Comp: $1.17MMs. Jean I. Liu J.D. (Age 55)M.S., Chief Legal Officer Comp: $1.11MMr. Charles R. Romp (Age 55)Exec. VP of Commercial U.S. Comp: $1.02MDr. Roger D. Dansey M.D. (Age 67)Pres of R&D Comp: $1.53MMr. David R. Epstein B.Sc. (Age 61)M.B.A., CEO & Director Dr. Vaughn B. Himes Ph.D. (Age 62)Chief Technical Officer Peggy PinkstonSr. VP of Investor RelationsMr. David CaouetteVP of Corp. CommunicationsMr. Matt SkeltonVP of MarketingMr. Christopher P. PawlowiczExec. VP of HRMore ExecutivesKey CompetitorsNeurocrine BiosciencesNASDAQ:NBIXRepligenNASDAQ:RGENBiogenNASDAQ:BIIBHalozyme TherapeuticsNASDAQ:HALOargenxNASDAQ:ARGXView All CompetitorsInsiders & InstitutionsNatixis Advisors L.P.Sold 1,058 shares on 1/27/2023Ownership: 0.013%Ballentine Partners LLCBought 2,036 shares on 1/27/2023Ownership: 0.001%D.B. Root & Company LLCSold 98 shares on 1/27/2023Ownership: 0.001%Sumitomo Mitsui DS Asset Management Company LtdSold 307 shares on 1/26/2023Ownership: 0.006%Dupont Capital Management CorpBought 438 shares on 1/26/2023Ownership: 0.001%View All Insider TransactionsView All Institutional Transactions SGEN Stock - Frequently Asked Questions Should I buy or sell Seagen stock right now? 16 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Seagen in the last year. There are currently 4 hold ratings and 12 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" SGEN shares. View SGEN analyst ratings or view top-rated stocks. What is Seagen's stock price forecast for 2023? 16 brokerages have issued 1-year target prices for Seagen's shares. Their SGEN share price forecasts range from $135.00 to $188.00. On average, they anticipate the company's stock price to reach $161.21 in the next year. This suggests a possible upside of 14.6% from the stock's current price. View analysts price targets for SGEN or view top-rated stocks among Wall Street analysts. How have SGEN shares performed in 2023? Seagen's stock was trading at $128.51 at the start of the year. Since then, SGEN shares have increased by 9.5% and is now trading at $140.67. View the best growth stocks for 2023 here. Are investors shorting Seagen? Seagen saw a increase in short interest in the month of January. As of January 15th, there was short interest totaling 3,000,000 shares, an increase of 15.4% from the December 31st total of 2,600,000 shares. Based on an average daily volume of 982,200 shares, the short-interest ratio is currently 3.1 days. View Seagen's Short Interest. When is Seagen's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 15th 2023. View our SGEN earnings forecast. How can I listen to Seagen's earnings call? Seagen will be holding an earnings conference call on Wednesday, February 15th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link. How were Seagen's earnings last quarter? Seagen Inc. (NASDAQ:SGEN) announced its quarterly earnings data on Thursday, October, 28th. The biotechnology company reported ($1.61) earnings per share for the quarter, missing analysts' consensus estimates of ($0.56) by $1.05. The biotechnology company had revenue of $424.60 million for the quarter, compared to analyst estimates of $384.83 million. Seagen had a negative trailing twelve-month return on equity of 21.56% and a negative net margin of 34.16%. The company's quarterly revenue was down 60.0% compared to the same quarter last year. During the same period in the prior year, the firm earned $3.50 EPS. What guidance has Seagen issued on next quarter's earnings? Seagen issued an update on its FY 2022 earnings guidance on Thursday, November, 3rd. The company provided EPS guidance of for the period. The company issued revenue guidance of $1.82 billion-$1.86 billion, compared to the consensus revenue estimate of $1.84 billion. What is Clay B. Siegall's approval rating as Seagen's CEO? 107 employees have rated Seagen Chief Executive Officer Clay B. Siegall on Glassdoor.com. Clay B. Siegall has an approval rating of 99% among the company's employees. This puts Clay B. Siegall in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Seagen own? Based on aggregate information from My MarketBeat watchlists, some companies that other Seagen investors own include NVIDIA (NVDA), AbbVie (ABBV), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Salesforce (CRM), QUALCOMM (QCOM), Tesla (TSLA), Micron Technology (MU), Netflix (NFLX) and Alibaba Group (BABA). What is Seagen's stock symbol? Seagen trades on the NASDAQ under the ticker symbol "SGEN." Who are Seagen's major shareholders? Seagen's stock is owned by a variety of institutional and retail investors. Top institutional investors include Manning & Napier Group LLC (0.19%), Pinnacle Associates Ltd. (0.13%), National Bank of Canada FI (0.10%), Allspring Global Investments Holdings LLC (0.07%), Gateway Investment Advisers LLC (0.01%) and DNB Asset Management AS (0.01%). Insiders that own company stock include Bros Advisors Lp Baker, Charles R Romp, Charles R Romp, Clay B Siegall, Clay B Siegall, Daniel G Welch, Daniel G Welch, David W Gryska, David W Gryska, Jean I Liu, Jean I Liu, Marc E Lippman, Morgan E Obrien, Roger D Dansey, Roger D Dansey, Todd E Simpson, Todd E Simpson, Vaughn B Himes and Vaughn B Himes. View institutional ownership trends. How do I buy shares of Seagen? Shares of SGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Seagen's stock price today? One share of SGEN stock can currently be purchased for approximately $140.67. How much money does Seagen make? Seagen (NASDAQ:SGEN) has a market capitalization of $26.12 billion and generates $1.57 billion in revenue each year. The biotechnology company earns $-674,470,000.00 in net income (profit) each year or ($3.45) on an earnings per share basis. How many employees does Seagen have? The company employs 2,675 workers across the globe. Does Seagen have any subsidiaries? The following companies are subsidiares of Seagen: Cascadian Therapeutics.Read More How can I contact Seagen? Seagen's mailing address is 21823 30TH DRIVE SE SUITE, BOTHELL WA, 98021. The official website for the company is www.seattlegenetics.com. The biotechnology company can be reached via phone at (425) 527-4000, via email at investors@seagen.com, or via fax at 425-527-4001. This page (NASDAQ:SGEN) was last updated on 1/28/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.